Adaptive announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers Adaptive Biotechnologies Corporation (Nasdaq: ADPT),...
